Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Moderate-to-Severe Atopic Dermatitis (Phase 3b Open-label)
2023-505558-16-00Phase 3Completed
- Sponsor
- Almirall
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Primary endpoint: Percentage of participants achieving EASI score ≤7 at Week 24. Started Oct 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-505558-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505558-16-00.